Glass House Brands (GLAS) Common Equity (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Common Equity of $76.9 million for Q1 2026, down 55.96% year-over-year from $174.6 million in Q1 2025, and up 3.97% quarter-over-quarter from $73.9 million in Q4 2025.
Glass House Brands (GLAS) Common Equity (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Common Equity for 7 consecutive years, with $76.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 55.96% year-over-year to $76.9 million; the TTM figure through Mar 2026 stood at $76.9 million (down 55.96% YoY), while the FY2025 annual figure was $73.9 million, down 36.39% from the prior year.
- Common Equity rose to $76.9 million in Q1 2026 per GLAS's latest filing, from $73.9 million in the prior quarter.
- Across five years, Common Equity topped out at $192.3 million in Q2 2025 and bottomed at $73.9 million in Q4 2025.
- Historically, Common Equity has averaged $142.4 million across 5 years, with a median of $159.5 million in 2023.
- Annual changes were most pronounced in 2022 — Common Equity surged 799.93% — and 2026, when it sank 55.96%.
- Glass House Brands' Common Equity stood at $168.9 million in 2022, then tumbled by 46.84% to $89.8 million in 2023, then grew by 29.49% to $116.2 million in 2024, then slumped by 36.39% to $73.9 million in 2025, then advanced by 3.97% to $76.9 million in 2026.
- Business Quant data shows GLAS's Common Equity at $76.9 million in Q1 2026, $73.9 million in Q4 2025, and $81.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Glass House Brands | 830.21 Mn | 811.66 Mn | 15.77 Mn | 72.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76.87 Mn |
| Dec 31, 2025 | 73.94 Mn |
| Sep 30, 2025 | 81.38 Mn |
| Jun 30, 2025 | 192.32 Mn |
| Mar 31, 2025 | 174.56 Mn |
| Dec 31, 2024 | 116.24 Mn |
| Sep 30, 2024 | 149.73 Mn |
| Jun 30, 2024 | 146.68 Mn |
| Mar 31, 2024 | 128.40 Mn |
| Dec 31, 2023 | 89.76 Mn |
| Sep 30, 2023 | 171.03 Mn |
| Jun 30, 2023 | 159.47 Mn |
| Mar 31, 2023 | 186.87 Mn |
| Dec 31, 2022 | 168.86 Mn |
| Sep 30, 2022 | 177.01 Mn |
| Jun 30, 2022 | 164.79 Mn |
| Mar 31, 2022 | 162.96 Mn |
| Dec 31, 2021 | 182.13 Mn |
| Sep 30, 2021 | 192.85 Mn |
| Jun 30, 2021 | 168.14 Mn |